ChEMBL ligand: CHEMBL445740 (Beta-Caryophylene, .beta.-caryophyllene, Beta-caryophyllene, Caryophyllene, (-)-(e)-caryophyllene, FEMA NO. 2252, NSC-11906, Trans-.beta.-caryophyllene, (-)-trans-caryophyllene, Trans-caryophyllene)
CB2 receptor/Cannabinoid CB2 receptor in Human [ChEMBL: CHEMBL253] [GtoPdb: 57] [UniProtKB: P34972] There should be some charts here, you may need to enable JavaScript!
Peroxisome proliferator-activated receptor-α/Peroxisome proliferator-activated receptor alpha in Human [ChEMBL: CHEMBL239] [GtoPdb: 593] [UniProtKB: Q07869] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
CB2 receptor/Cannabinoid CB2 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL253] [GtoPdb: 57] [UniProtKB: P34972]
GtoPdb	Measuring displacement of [3H]CP55940 from human CB2 expressed in CHOK1 cell membranes	-	6.82	pKi	150	nM	Ki	Eur J Med Chem (2018) 157: 198-228 [PMID:30096653]
ChEMBL	Displacement of [3H]CP55940 from human CB2 expressed in CHOK1 cell membranes after 2 hrs by liquid scintillation counting method	B	6.82	pKi	150	nM	Ki	Eur J Med Chem (2018) 157: 198-228 [PMID:30096653]
GtoPdb	Agonist potency at recombinant human CB2 receptor expressed in CHOK1 cells; determined as inhibition of forskolin-stimulated cAMP formation.	-	5.72	pEC50	1900	nM	EC50	Eur J Med Chem (2018) 157: 198-228 [PMID:30096653]
ChEMBL	Agonist activity at recombinant human Cb2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-stimulated cAMP levels measured up to 30 mins by luminescence assay	F	5.72	pEC50	1900	nM	EC50	Eur J Med Chem (2018) 157: 198-228 [PMID:30096653]
Peroxisome proliferator-activated receptor-α/Peroxisome proliferator-activated receptor alpha in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL239] [GtoPdb: 593] [UniProtKB: Q07869]
ChEMBL	Agonist activity at PPARalpha (unknown origin)	B	5.02	pEC50	9580	nM	EC50	Eur J Med Chem (2021) 221: 113535-113535 [PMID:33992930]

ChEMBL data shown on this page come from version 34:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]